AMRI Albany Molecular Research Inc.
Exchange
NASDAQSector
Health CareIndustry
Biotechnology: Commercial Physical & Biological ResarchMarket Cap.
340.7M
Grade
22.55/100
Current Price
$11.05
+0.08 (+0.73%) Company Metrics
- 51.02 P/E
- 1.46 P/S
- 1.58 P/B
- 0.215 EPS
- 0.95% Cash ROIC
- 0.53 Cash Ratio
- 0.00 / N/A % Dividend
- 429,121.00 Avg. Vol.
- 30.83M Shares
- 340.7M Market Cap.
Company Description
Albany Molecular Research, Inc. provides contract services to various pharmaceutical and biotechnology companies primarily in the United States, Europe, and Asia. The company offers a range of drug discovery services, including assay development and design, screening, screening library, natural product, medicinal chemistry, computer-aided drug discovery, in vitro ADMET, and bioanalytical services....
more
News
ALBANY MOLECULAR RESEARCH, INC. : AMRI CFO to Present at the UBS ...
4-traders (press release) - May 15, 2013
4-traders (press release) - May 15, 2013
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services.
Hologic Inc. (NASDAQ:HOLX), Albany Molecular Research Inc. (NASDAQ:AMRI ...
SBWire (press release) - May 8, 2013
SBWire (press release) - May 8, 2013
Albany Molecular Research Inc. (NASDAQ:AMRI) a contract research and manufacturing organization that offers drug discovery, development, and manufacturing services to pharmaceutical and biotechnology companies in the United States, Europe, and ...
Stocks to Watch: Albany Molecular Research, Pike Electric Corporation, USEC ...
SBWire (press release) - May 8, 2013
SBWire (press release) - May 8, 2013
Albany Molecular Research, Inc.(NASDAQ:AMRI) shares fell 14.31% to $10.48. The company on May 7 reported financial and operating results for the first quarter ended March 31, 2013.
ALBANY MOLECULAR RESEARCH, INC. : AMRI to Announce First Quarter ...
4-traders (press release) - Apr 24, 2013
4-traders (press release) - Apr 24, 2013
ALBANY, N.Y., April 24, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it will issue first quarter financial results before the opening of the market on Tuesday, May 7, 2013.
Albany Molecular Research Inc. (NASDAQ:AMRI), Xenoport, Inc. (NASDAQ ...
SBWire (press release) - Apr 28, 2013
SBWire (press release) - Apr 28, 2013
New York, NY -- (SBWIRE) -- 04/28/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Albany Molecular Research Inc. (NASDAQ:AMRI), Xenoport, Inc. (NASDAQ:XNPT), and Meridian Bioscience, Inc. (NASDAQ:VIVO).
Stocks in Positive Territory: Corelogic Inc (NYSE:CLGX), Albany Molecular ...
NIS - Apr 26, 2013
NIS - Apr 26, 2013
New York, NY - (NISMAGAZINE) - 4/25/2013- Corelogic Inc (NYSE:CLGX) gained 7.37% at $26.52 after trading 3.08 million shares.
Albany Molecular Research (AMRI) Releases Quarterly Earnings Results
Mideast Time - May 7, 2013
Mideast Time - May 7, 2013
Albany Molecular Research logo Albany Molecular Research (NASDAQ: AMRI) issued its quarterly earnings data on Tuesday.
Loss swings to profit in first quarter - Albany Times Union Research and Markets: Medicinal and Botanical Manufacturing Industry - 2013 ...
Fort Mills Times - 1 hour ago
Fort Mills Times - 1 hour ago
AAIPharma Inc., Albany Molecular Research, Inc., Alkermes, Inc., Baxter International Inc., Chattem, Inc., Endo Pharmaceuticals Holdings Inc., Herbalife Ltd.
Fed. Circ. Flips Noninfringement Judgment In Allegra IP Row
Law360 (subscription) - May 20, 2013
Law360 (subscription) - May 20, 2013
Law360, New York (May 20, 2013, 5:34 PM ET) -- Aventis Pharmaceuticals Inc. and Albany Molecular Research Inc. on Monday convinced the Federal Circuit to reverse a noninfringement judgment over an Albany Molecular patent covering processes used ...
Semi-Annual Changes to the NASDAQ Biotechnology Index
Wall Street Journal (press release) - May 13, 2013
Wall Street Journal (press release) - May 13, 2013
... will be added to the Index: ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD); Albany Molecular Research, Inc. (Nasdaq:AMRI); Anacor Pharmaceuticals, Inc. (Nasdaq:ANAC); Clovis Oncology, Inc. (Nasdaq:CLVS); Furiex Pharmaceuticals, Inc. (Nasdaq:FURX); ...


